
Luca Lovrecic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9153842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11023-11028.	7.1	393
2	An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biology, 2014, 15, R53.	9.6	101
3	Therapeutic perspectives of epigenetically active nutrients. British Journal of Pharmacology, 2015, 172, 2756-2768.	5.4	99
4	Sodium phenylbutyrate in Huntington's disease: A doseâ€finding study. Movement Disorders, 2007, 22, 1962-1964.	3.9	79
5	Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape. Journal of Community Genetics, 2018, 9, 117-132.	1.2	68
6	Nutriepigenomics. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 328-333.	2.5	64
7	Points to consider for laboratories reporting results from diagnostic genomic sequencing. European Journal of Human Genetics, 2018, 26, 36-43.	2.8	58
8	Comprehensive use of extended exome analysis improves diagnostic yield in rare disease: a retrospective survey in 1,059 cases. Genetics in Medicine, 2018, 20, 303-312.	2.4	57
9	Phenotype-driven gene target definition in clinical genome-wide sequencing data interpretation. Genetics in Medicine, 2016, 18, 1102-1110.	2.4	41
10	Association of circadian rhythm genes ARNTL/BMAL1 and CLOCK with multiple sclerosis. PLoS ONE, 2018, 13, e0190601.	2.5	34
11	Gene expression changes in blood as a putative biomarker for Huntington's disease. Movement Disorders, 2009, 24, 2277-2281.	3.9	28
12	Expression Signature as a Biomarker for Prenatal Diagnosis of Trisomy 21. PLoS ONE, 2013, 8, e74184.	2.5	27
13	No Specific Gene Expression Signature in Human Granulosa and Cumulus Cells for Prediction of Oocyte Fertilisation and Embryo Implantation. PLoS ONE, 2015, 10, e0115865.	2.5	24
14	Transcriptomic Analysis and Meta-Analysis of Human Granulosa and Cumulus Cells. PLoS ONE, 2015, 10, e0136473.	2.5	23
15	Mutations in the hemochromatosis gene (HFE) and multiple sclerosis. Neuroscience Letters, 2005, 383, 301-304.	2.1	22
16	Tumor Necrosis Factor-α-308 Gene Polymorphism in Croatian and Slovenian Multiple Sclerosis Patients. European Neurology, 2007, 57, 203-207.	1.4	22
17	Specific gene expression differences in cumulus cells as potential biomarkers of pregnancy. Reproductive BioMedicine Online, 2015, 30, 426-433.	2.4	22
18	Region with persistent high frequency of multiple sclerosis in Croatia and Slovenia. Journal of the Neurological Sciences, 2006, 247, 169-172.	0.6	21

LUCA LOVRECIC

#	Article	IF	CITATIONS
19	Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. Acta Neurologica Scandinavica, 2006, 114, 374-377.	2.1	20
20	Epidemiology of Huntington's disease in Slovenia. Acta Neurologica Scandinavica, 2009, 119, 371-375.	2.1	18
21	Human Y-specific STR haplotypes in the Western Croatian population sample. Forensic Science International, 2005, 149, 257-261.	2.2	17
22	Clinical utility of array comparative genomic hybridisation in prenatal setting. BMC Medical Genetics, 2016, 17, 81.	2.1	16
23	No association of CCR5D32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Multiple Sclerosis Journal, 2006, 12, 360-362.	3.0	15
24	Recommendations for reporting results of diagnostic genomic testing. European Journal of Human Genetics, 2022, 30, 1011-1016.	2.8	15
25	11q terminal deletion and combined immunodeficiency (Jacobsen syndrome): Case report and literature review on immunodeficiency in Jacobsen syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 3237-3240.	1.2	14
26	PAI and TPA gene polymorphisms in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 243-247.	3.0	13
27	Diagnostic efficacy and new variants in isolated and complex autism spectrum disorder using molecular karyotyping. Journal of Applied Genetics, 2018, 59, 179-185.	1.9	12
28	Interleukin 7 receptor alpha polymorphism rs6897932 and susceptibility to multiple sclerosis in the Western Balkans. Multiple Sclerosis Journal, 2010, 16, 533-536.	3.0	11
29	The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis. Disease Markers, 2014, 2014, 1-8.	1.3	10
30	Chronic Lymphocytic Leukemia with Divergent Richter's Transformation into a Clonally Related Classical Hodgkin's and Plasmablastic Lymphoma: A Case Report. Case Reports in Oncology, 2020, 13, 120-129.	0.7	9
31	Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome. Genetics in Medicine, 2022, 24, 1283-1296.	2.4	9
32	ADP-Ribosylation Factor Guanine Nucleotide-Exchange Factor 2 (ARFGEF2): A New Potential Biomarker in Huntington's Disease. Journal of International Medical Research, 2010, 38, 1653-1662.	1.0	8
33	MMP-2 â^'1575G/A polymorphism modifies the onset of optic neuritis as a first presenting symptom in MS?. Journal of Neuroimmunology, 2015, 286, 13-15.	2.3	8
34	Transcriptome Profiling Uncovers Potential Common Mechanisms in Fetal Trisomies 18 and 21. OMICS A Journal of Integrative Biology, 2017, 21, 565-570.	2.0	8
35	Interstitial deletion 2p11.2–p12: Further delineation. American Journal of Medical Genetics, Part A, 2009, 149A, 2324-2326.	1.2	7
36	Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients. Pharmacogenetics and Genomics, 2017, 27, 232-235.	1.5	7

LUCA LOVRECIC

#	Article	IF	CITATIONS
37	Combination of QFâ€PCR and aCGH is an efficient diagnostic strategy for the detection of chromosome aberrations in recurrent miscarriage. Molecular Genetics & Genomic Medicine, 2019, 7, e980.	1.2	7
38	The interleukin-1 receptor antagonist gene and the inhibitor of kappa B-like protein gene polymorphisms are not associated with myocardial infarction in Slovene population with type 2 diabetes. Collegium Antropologicum, 2007, 31, 503-7.	0.2	7
39	Direct-to-consumer genetic testing in Slovenia: availability, ethical dilemmas and legislation. Biochemia Medica, 2015, 25, 84-89.	2.7	6
40	A New Case of an Extremely Rare 3p21.31 Interstitial Deletion. Molecular Syndromology, 2016, 7, 93-98.	0.8	6
41	Angiotensin-Converting Enzyme Gene Polymorphism in Patients with Multiple Sclerosis from Bosnia and Herzegovina. Genetic Testing and Molecular Biomarkers, 2011, 15, 835-838.	0.7	5
42	Brachytelephalangic chondrodysplasia punctata caused by new small hemizygous deletion in a boy presenting with hearing loss. Molecular Cytogenetics, 2015, 8, 83.	0.9	4
43	Microduplication in the 2p16.1p15 chromosomal region linked to developmental delay and intellectual disability. Molecular Cytogenetics, 2018, 11, 39.	0.9	4
44	Polymorphism of the ADRB2 rs1042713 gene is not associated with spontaneous preterm birth: Analyses in a Slovenian sample and meta analysis. Balkan Journal of Medical Genetics, 2017, 20, 35-41.	0.5	4
45	The Endometrial Transcriptome of Metabolic and Inflammatory Pathways During the Window of Implantation Is Deranged in Infertile Obese Polycystic Ovarian Syndrome Women. Metabolic Syndrome and Related Disorders, 2022, 20, 384-394.	1.3	4
46	Characterization of a de novo sSMC 17 detected in a girl with developmental delay and dysmorphic features. Molecular Cytogenetics, 2017, 10, 10.	0.9	3
47	The frequency of CNV s in a cohort population of consecutive fetuses with congenital anomalies after the termination of pregnancy. Molecular Genetics & amp; Genomic Medicine, 2019, 7, e658.	1.2	3
48	A new case of rare proximal 3q13 interstitial deletion. Open Medicine (Poland), 2011, 6, 625-630.	1.3	2
49	SATB2 haploinsufficiency in patients with cleft palate. Open Medicine (Poland), 2010, 5, 318-321.	1.3	0
50	Genomic Testing for Prenatal Clinical Evaluation of Congenital Anomalies. , 2018, , .		0
51	ldentification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines. BMC Cancer, 2021, 21, 665.	2.6	0
52	Potential protective role of a NOD2 polymorphism in the susceptibility to multiple sclerosis is not associated with interferon therapy. Biomedical Reports, 2021, 15, 100.	2.0	0